KEYNOTE-811 (NCT03615326) is a phase III trial comparing pembrolizumab plus trastuzumab in combination with chemotherapy versus placebo plus trastuzumab in combination with  chemotherapy as first-line treatment in HER2-positive advanced GC; this study plans to enroll 730 patients (Table 3). This evidence concerns the gene ERBB2 and gastric cancer.